Pharmacokinetic data for lopinavir in late pregnancy and in breastfeeding are limited, and no data for abacavir in breast milk are available.
Methods
Women in the Mma Bana Study initiated HAART from 18 to 34 weeks of gestation. We determined trough plasma and whole breast milk concentrations of lopinavir (LPV), abacavir (ABC), nevirapine (NVP), lamivudine (3TC) and zidovudine (ZDV) among separate subsets of pregnant and breastfeeding women, and in plasma of exposed infants. Lopinavir was measured 1 month after starting HAART or 1 month postpartum, and other drugs were measured 1 month postpartum.
Results
Sampling occurred a median of 14 h (range 11–17) from last maternal drug ingestion. Although 50% higher median LPV levels were seen in postpartum than antepartum plasma (8.29 μg/ml versus 5.51 μg/ml; P=0.02), antepartum levels with standard LPV dosing were therapeutic for all women (>1.0 μg/ml). Very low LPV levels (<0.25 μg/ml) were detected in breast milk. Median ABC levels in breast milk were 85% of those in plasma (0.057 μg/ml versus 0.067 μg/ml). Breast milk concentrations of NVP and 3TC were 27% and 74% of plasma levels, respectively. At these trough maternal time points, only NVP was detectable in potentially inhibitory levels in breastfeeding infants, and most infants had non-detectable levels of LPV, ABC, ZDV and 3TC via maternal breast milk.
Conclusions
Standard LPV dosing achieved therapeutic levels in pregnancy and no appreciable concentrations in breast milk. ABC is detectable in breast milk at similar concentrations to plasma, but does not result in appreciable infant exposure.
References
1.
ShapiroR.L., HughesM.D., OgwuA.Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med2010; 362: 2282–2294.
2.
ThomasT., MasabaR., NdivoR.Prevention of mother-to-child transmission of HIV-1 among breastfeeding mothers using HAART: The Kisumu Breastfeeding Study, Kisumu, Kenya, 2003–2007.15th CROI. 3–6 February 2008 Boston, MA, USA. Abstract 45aLB.
3.
Kesho Bora Study Group, de VincenziI.Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis2011; 11: 171–180.
4.
ChaselaC.S., HudgensM.G., JamiesonD.J.Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med2010; 362: 2271–2281.
5.
ShapiroR.L., HollandD.T., CapparelliE.Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis2005; 192: 720–727.
6.
MirochnickM., ThomasT., CapparelliE.Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother2009; 53: 1170–1176.
7.
MirochnickM., BestB.M., StekA.M.Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr2008; 49: 485–491.
8.
MirochnickM., FentonT., GagnierP.Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis1998; 178: 368–374.
9.
StekA.M., MirochnickM., CapparelliE.Reduced lopinavir exposure during pregnancy. AIDS2006; 20: 1931–1939.
10.
ParkinN.T., HellmannN.S., WhitcombJ.M., KissL., ChappeyC., PetropoulosC.J.Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother2004; 48: 437–443.
11.
RamautarsingR.A., van der LugtJ., GorowaraM.Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS2011; 25: 1299–1303.
12.
CresseyT.R., JourdainG., RawangbanB.PHPT-5 Team. Pharmacokinetics and virologic response of zidovudine/ lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS2010; 24: 2193–2200.
13.
LyonsF., LecheltM., De RuiterA.Steady-state lopinavir levels in third trimester of pregnancy. AIDS2007; 21: 1053–1054.
14.
Bouillon-PichaultM., JullienV., AzriaE.Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother2009; 63: 1223–1232.
15.
ElseL.J., DouglasM., DickinsonL., BackD.J., KhooS.H., TaylorG.P.Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother2012; 56: 816–824.
16.
KumarP.N., SweetD.E., McDowellJ.A.Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother1999; 43: 603–608.
